Literature DB >> 33516603

Cut-off values of skeletal muscle index and psoas muscle index at L3 vertebra level by computerized tomography to assess low muscle mass.

Gulistan Bahat1, Banu Ozulu Turkmen2, Samil Aliyev3, Nezahat Muge Catikkas2, Baris Bakir3, Mehmet Akif Karan2.   

Abstract

BACKGROUND & AIMS: Computerized tomography (CT) is considered the gold standard for the evaluation of total skeletal muscle quantity. Skeletal muscle assessments at the L3 vertebra level revealed significantly correlated with total body muscle measurements. Clinicians need cut-offs to evaluate low muscle mass in various patients who already had CT imaging without any additional cost. This assessment is important to help the physicians to stratify the patients for mortality and other complications. It may also enable the diagnosis of malnutrition by the GLIM criteria. Few studies reported cut-offs in different populations. We aimed to provide cut-off values for total skeletal muscle index (SMI) and psoas muscle mass index (PMI) at the L3 vertebra level in the Turkish population.
METHODS: We assessed the preoperative plain CT images of living adult liver donors who were admitted to a single transplantation center between June 2010 and April 2018. We derived cut-off values with two alternative methods, the 5th percentile value or mean minus two standard deviations and from two groups of study participants, i.e. the total study population and the younger subgroup aged between 18 and 40.
RESULTS: The study population involved 601 subjects with a mean age of 32.5 ± 9 (range: 18-59 years) and 326 (54.2%) was male. The younger subgroup was composed of 482 individuals with a mean age of 28.8 ± 5.9 and 55.6% male. In patients aged between 18 and 40, PMI and SMI cut-offs by using the 5th percentile were 5.40 cm2/m2, 41.42 cm2/m2 for males; and 3.56 cm2/m2, 30.70 cm2/m2 for females; respectively. The cut-offs of PMI and SMI by using mean minus two standard deviations were 4.62 cm2/m2, 38.67 cm2/m2 for males; and 2.66 cm2/m2, 27.8 cm2/m2 for females; respectively. These cut-offs were comparable to the other populations.
CONCLUSIONS: Our study provided cut-offs to be used in CT images for PMI and SMI. There is a need for further longitudinal studies to verify whether these cut-offs are successful in predicting mortality or other adverse outcomes associated with low muscle mass.
Copyright © 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Entities:  

Keywords:  Computerized tomography; Cut-off value; Imaging; Lumbar 3 vertebra; Muscle mass; Sarcopenia

Mesh:

Year:  2021        PMID: 33516603     DOI: 10.1016/j.clnu.2021.01.010

Source DB:  PubMed          Journal:  Clin Nutr        ISSN: 0261-5614            Impact factor:   7.324


  5 in total

1.  Psoas Muscle Index Can Be Used to Predict Long-Term Mortality in Young Male Patients With Acute-on-Chronic Liver Failure.

Authors:  Manman Xu; Tongzeng Li; Ming Kong; Nan Geng; Wenyan Song; Guanya Guo; Zhongping Duan; Ying Han; Yu Chen
Journal:  Front Nutr       Date:  2022-02-18

2.  Low muscle mass in COVID-19 critically-ill patients: Prognostic significance and surrogate markers for assessment.

Authors:  I A Osuna-Padilla; N C Rodríguez-Moguel; S Rodríguez-Llamazares; C E Orsso; C M Prado; M A Ríos-Ayala; O Villanueva-Camacho; A Aguilar-Vargas; L E Pensado-Piedra; F Juárez-Hernández; C M Hernández-Cárdenas
Journal:  Clin Nutr       Date:  2022-03-01       Impact factor: 7.324

3.  Serum creatinine to cystatin C ratio reflects preoperative and early postoperative walking ability in older patients with hip fracture.

Authors:  Naoki Okubo; Takashi Yoshida; Kazuya Tanaka; Naoya Okada; Kunihiko Hosoi; Masato Ohara; Kenji Takahashi
Journal:  J Cachexia Sarcopenia Muscle       Date:  2022-02-15       Impact factor: 12.910

Review 4.  Progress in Applicability of Scoring Systems Based on Nutritional and Inflammatory Parameters for Ovarian Cancer.

Authors:  Juan Mu; Yue Wu; Chen Jiang; Linjuan Cai; Dake Li; Jian Cao
Journal:  Front Nutr       Date:  2022-04-08

5.  Association of sarcopenia with survival in advanced NSCLC patients receiving concurrent immunotherapy and chemotherapy.

Authors:  Fabian J Bolte; Sloane McTavish; Nathan Wakefield; Lindsey Shantzer; Caroline Hubbard; Arun Krishnaraj; Wendy Novicoff; Ryan D Gentzler; Richard D Hall
Journal:  Front Oncol       Date:  2022-09-23       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.